{{ infobox
| gene = SCFD1
| name = Sec1 Family Domain Containing 1
| chromosome = 9q34.3
| ncbi_gene_id = 23256
| ensembl = ENSG00000084112
| uniprot = Q8WVM8
| diseases = Amyotrophic Lateral Sclerosis, Frontotemporal Dementia, Spinal Muscular Atrophy
}}
SCFD1 (Sec1 Family Domain Containing 1), also known as Sedlin or Sly1, is a member of the Sec1/Munc18 (SM) protein family that plays essential roles in intracellular vesicle trafficking and membrane fusion events throughout the cell.[1] SCFD1 is a critical regulator of SNARE (Soluble N-ethylmaleimide-sensitive factor Attachment Protein Receptor) complex assembly and is particularly important in neurons for synaptic vesicle cycling and axonal transport.[2] Mutations in SCFD1 have been implicated in amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases affecting motor neurons.[3]
The SCFD1 gene is located on chromosome 9q34.3 and encodes a 372 amino acid protein with a molecular weight of approximately 41 kDa. The gene consists of 14 exons and exhibits ubiquitous expression across tissue types, with particularly high expression in the central nervous system.[4]
SCFD1 contains:
SCFD1 functions as a critical regulator of membrane fusion through multiple mechanisms:[1:1][2:1]
SNARE Complex Regulation:
ER-Golgi Transport:
Synaptic Vesicle Cycling:
SCFD1 interacts with:
SCFD1 is a significant ALS risk gene with multiple disease mechanisms:[3:1][7]
Genetic Evidence:
Molecular Mechanisms:
Therapeutic Implications:
SCFD1 is highly expressed in:
In ALS, SCFD1 dysfunction leads to:[3:2][7:1]
SCFD1 in vesicle trafficking: Structure and function (Journal of Cell Science, 2020). 2020. ↩︎ ↩︎
SM proteins in synaptic vesicle cycling (Nature Reviews Neuroscience, 2019). 2019. ↩︎ ↩︎
SCFD1 mutations in ALS: Genetic and functional studies (Nature Neuroscience, 2014). 2014. ↩︎ ↩︎ ↩︎
SCFD1 expression in human brain (Brain Research, 2016). 2016. ↩︎ ↩︎
SM protein regulation of SNARE assembly (Cell, 2019). 2019. ↩︎
Impaired synaptic vesicle trafficking in ALS (Brain, 2021). 2021. ↩︎ ↩︎
Axonal transport defects in neurodegeneration (Neuron, 2022). 2022. ↩︎ ↩︎
SCFD1 and schizophrenia: GWAS findings (Molecular Psychiatry, 2018). 2018. ↩︎
Therapeutic targeting of synaptic vesicle proteins in ALS (EMBO Molecular Medicine, 2023). 2023. ↩︎